Related Experiment Videos
[High-dose brachytherapy in endobronchial neoplastic stenoses]
P Corsa1, S S Parisi, A Raguso
1Servizio di Radioterapia, Ospedale I.R.C.C.S. Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG.
La Radiologia Medica
|July 1, 1997
Summary
High dose rate (HDR) brachytherapy effectively palliates endobronchial lung cancer symptoms, improving quality of life. This HDR brachytherapy offers accurate, well-tolerated treatment for patients with poor prognoses.
Area of Science:
- Oncology
- Radiotherapy
Background:
- Endobronchial neoplastic stenosis significantly impacts patient quality of life.
- Palliative treatment options for advanced lung cancer are crucial.
Purpose of the Study:
- To evaluate the efficacy and safety of high dose rate (HDR) brachytherapy for endobronchial neoplastic stenosis.
- To assess symptom palliation and patient outcomes.
Main Methods:
- Twenty-nine patients with endobronchial neoplastic stenosis received HDR brachytherapy.
- Doses ranged from 5 to 21 Gy total, with fraction doses of 5 to 15 Gy.
- Patient outcomes, including symptom relief and survival, were monitored.
Main Results:
- Subjective symptom response in 78.4% of patients (67.6% complete remission).
- Complete remission of hemoptysis in 100% of patients; significant improvement in dyspnea (70%), cough (46.4%), and atelectasis (83.2%).
- A complication rate of 13.8% was observed.
Conclusions:
- HDR endobronchial brachytherapy is effective for palliation of lung cancer symptoms.
- The HDR technique offers advantages in accuracy and tolerability over LDR.
- Further clinical trials are warranted to optimize HDR brachytherapy protocols for curative intent.